Fig. 1.

Comparison of NNV003 and lilotomab with respect to effector molecules binding, ADCP, ADCC, cytotoxicity and therapeutic effect in vivo. Binding of NNV003 and lilotomab to (a) hFcγRs, (b) mFcγRs and (c) human FcRn at neutral and acidic pH. (d) ADCP and (e) ADCC induction of NNV003, lilotomab and rituximab in different target cells. (f) Specific lysis of four target cell lines by ADCC of NNV003, lilotomab and rituximab. (g) Cytotoxicity of NNV003 and (h) in vivo efficacy of 100 μg NNV003 and lilotomab, injected twice a week for 4 weeks, in CB17 SCID mice i.v. injected with REC-1 cells